Status:
COMPLETED
Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Arthroscopy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To compare total analgesic use at 24 hours after arthroscopic knee surgery in celecoxib-treated versus placebo-treated patients
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed (or suspected to have) meniscus trauma of the knee requiring ambulatory arthroscopic knee surgery
- Willing to participate in study for 36 hours and come to follow-up visit 7 days post surgery
Exclusion
- Exclusion criteria:
- Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
- Received acetaminophen or low dose narcotic (vicodin/tylox) within 8 hours of surgery
- Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or intra-artcular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00633438
Start Date
January 1 2004
End Date
June 1 2004
Last Update
February 21 2021
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
2
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33713
3
Pfizer Investigational Site
Baltimore, Maryland, United States, 21218
4
Pfizer Investigational Site
Timonium, Maryland, United States, 21093